Point72 Asia (Singapore) Pte. Ltd. Compass Therapeutics, Inc. Call Options Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $381 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding CMPX
# of Institutions
127Shares Held
101MCall Options Held
2.52MPut Options Held
3.1M-
Orbimed Advisors LLC San Diego, CA22.4MShares$45.6 Million1.32% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$22.5 Million1.36% of portfolio
-
Blackstone Inc New York, NY10MShares$20.5 Million0.09% of portfolio
-
Bio Impact Capital LLC Cambridge, MA8.44MShares$17.2 Million2.97% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$13.5 Million0.0% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $207M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...